Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Rhea-AI Summary

Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.

The event is scheduled for December 16, 2025 at 8:00 AM ET / 5:00 AM PT. Results will be released in a morning press release and presented on the webcast; slides and the press release will be posted in the company's events section at https://ir.nektar.com/events-and-presentations/events. A replay will be available for at least 30 days after the event.

News Market Reaction

-2.56%

20 alerts

-2.56% News Effect

+7.3% Peak Tracked

-18.9% Trough Tracked

-$28M Valuation Impact

$1.08B Market Cap

1.0x Rel. Volume

On the day this news was published, NKTR declined 2.56%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -18.9% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $28M from the company's valuation, bringing the market cap to $1.08B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Induction period length: 36 weeks Trial phase: Phase 2b Call date: December 16, 2025 +3 more

6 metrics

Induction period length 36 weeks Induction treatment period in REZOLVE-AA Phase 2b trial

Trial phase Phase 2b REZOLVE-AA study of rezpegaldesleukin in alopecia areata

Call date December 16, 2025 Scheduled topline results conference call and webcast

Event time ET 8:00 am ET Start of topline results investor call

Event time PT 5:00 am PT Start of topline results investor call

Webcast replay length 30 days Replay availability following the topline results webcast

Market Reality Check

Price: $66.33 Vol: Volume 425,557 is below t...

normal vol

$66.33 Last Close

Volume Volume 425,557 is below the 20-day average of 602,573 ahead of the topline call. normal

Technical Shares at $53.30 are trading above the $30.85 200-day MA, reflecting a strong prior uptrend.

Peers on Argus

Peers show a mixed tape: QURE +4.29% and ABUS +4.87% while SANA -1.55% and SYRE ...

1 Up

Peers show a mixed tape: QURE +4.29% and ABUS +4.87% while SANA -1.55% and SYRE -1.74%. Only QURE appeared on momentum scans, up ~11.6% without same-day news, suggesting NKTR’s setup into the Rezpegaldesleukin readout is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Equity inducement grants	Neutral	+0.7%	Reported stock option inducement grants for two new hires under 2025 plan.
Nov 08	Clinical data update	Positive	+3.6%	Phase 2b REZOLVE-AD data showed significant efficacy in asthma and dermatitis.
Nov 06	Quarterly earnings	Neutral	+1.6%	Q3 2025 results with cash runway to Q2 2027 and recent capital raises.
Oct 30	Conference participation	Neutral	+5.3%	Announced Jefferies Global Healthcare Conference fireside chat and webcast.
Oct 28	Earnings date notice	Neutral	-2.6%	Scheduled Q3 2025 earnings release and investor conference call details.

Pattern Detected

Recent news, especially clinical and financing updates, has generally coincided with modestly positive price moves, with even neutral conference items sometimes followed by stronger gains.

Recent Company History

Over the past few months, Nektar has balanced financial updates with growing clinical visibility. The company reported Q3 2025 results on Nov 6, highlighting $270.2M in cash and ongoing Phase 2b programs. Multiple conference and earnings-date announcements on Oct 28 and Oct 30 framed an active investor-relations cadence. More recently, REZOLVE-AD Phase 2b data on Nov 8 showed statistically significant, clinically meaningful results, and inducement grants were reported on Dec 5. Today’s alopecia areata topline call continues this pattern of structured, trial-focused communication.

Market Pulse Summary

This announcement sets expectations for topline 36-week induction data from the REZOLVE-AA Phase 2b ...

Analysis

This announcement sets expectations for topline 36-week induction data from the REZOLVE-AA Phase 2b study of rezpegaldesleukin in severe-to-very-severe alopecia areata. It continues a pattern of structured communication following prior REZOLVE-AD updates and Q3 2025 financial disclosures. Investors may track how this readout complements earlier immunology data, the timeline of subsequent development steps, and how ongoing operating losses balance against a reported cash position of $270.2M as of Q3 2025.

Key Terms

phase 2b, regulatory t-cell (treg), alopecia areata, webcast

4 terms

phase 2b medical

"ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

regulatory t-cell (treg) medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe"

Regulatory T cells (Tregs) are a specialized type of immune cell that act like peacekeepers, calming or restraining other immune cells to prevent excessive inflammation or attacks on the body’s own tissues. For investors, Tregs matter because they are key targets or safety considerations in drug development: boosting them can treat autoimmune disease while blocking them can help cancer therapies, so therapies that affect Tregs can drive both efficacy and risk.

alopecia areata medical

"rezpegaldesleukin ... for severe-to-very-severe alopecia areata on Tuesday, December 16"

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

webcast technical

"will host an investor call and live webcast to review topline results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT. 

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:
Vivian Wu
628-895-0661

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025-302642737.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) present topline REZOLVE-AA 36-week results?

Nektar will present topline results on December 16, 2025 at 8:00 AM ET / 5:00 AM PT.

Where can investors watch the Nektar (NKTR) REZOLVE-AA webcast on December 16, 2025?

Investors can access the live webcast via the company events page at https://ir.nektar.com/events-and-presentations/events.

Will Nektar (NKTR) release results before the webcast on December 16, 2025?

Yes. The company will provide a morning press release with the topline results before the webcast.

How long will the Nektar (NKTR) webcast replay be available after the December 16, 2025 presentation?

A replay of the webcast will be available for at least 30 days following the event.

What trial period do the presented REZOLVE-AA results cover for Nektar (NKTR)?

The presentation covers topline data from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial.

What is rezpegaldesleukin, the drug discussed by Nektar (NKTR) on December 16, 2025?

Rezpegaldesleukin is described as an investigational regulatory T-cell (Treg) proliferator being studied for severe-to-very-severe alopecia areata.